WO2014182101A1 - 저분자 메틸셀룰로오스 기반의 비경구 약물 전달 시스템 - Google Patents
저분자 메틸셀룰로오스 기반의 비경구 약물 전달 시스템 Download PDFInfo
- Publication number
- WO2014182101A1 WO2014182101A1 PCT/KR2014/004120 KR2014004120W WO2014182101A1 WO 2014182101 A1 WO2014182101 A1 WO 2014182101A1 KR 2014004120 W KR2014004120 W KR 2014004120W WO 2014182101 A1 WO2014182101 A1 WO 2014182101A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- drug
- gel
- molecular weight
- drug delivery
- present
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
- A61K38/385—Serum albumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/14—Preparation of compounds containing saccharide radicals produced by the action of a carbohydrase (EC 3.2.x), e.g. by alpha-amylase, e.g. by cellulase, hemicellulase
Definitions
- the present invention relates to a parenteral drug delivery system. More specifically, the present invention relates to a parenteral drug delivery system using a thermosensitive gel based solely on low molecular weight polysaccharide methylcellulose without salt salts.
- Negative temperature sensitive polymers with a lower critical solution temperature (LCST) or temperature-reversible hydrogels exhibiting a reversible gel-sol transition behavior upon heating or cooling are the most suitable for stimulus-sensitive polymer systems for drug delivery. It is a commonly studied field.
- Korean Patent No. 10-0813224 of the present inventors discloses a drug delivery system for protein delivery based on high molecular weight methylcellulose and coacervate in natural polymers.
- drug delivery technology using a polymer drug delivery technology using a protein drug, a drug delivery system and a gel depot drug delivery system using a PLGA-PEG-PLGA synthetic polymer are known.
- the inventors of the present invention have completed the present invention by finding that natural polymer methyl cellulose having low molecular weight can be effectively used as a temperature-sensitive gel for parenteral drug delivery without using salt salts. .
- thermosensitive gel for parenteral drug delivery with high biocompatibility and biodegradability and a method for preparing the same.
- the present invention provides a temperature-sensitive gel for parenteral drug delivery consisting of methyl cellulose having a molecular weight of 10 to 20 kDa without salt salts.
- the present invention also provides a sustained-release parenteral drug delivery composition
- a sustained-release parenteral drug delivery composition comprising the thermosensitive gel and a hydrophilic drug, a protein drug or a nucleic acid-based drug.
- the temperature-reversible methyl cellulose having a molecular weight of 10 to 20 kDa preferably has an average molecular weight of 15 kDa, and turns into a gel in a body temperature range of 35 to 40 ° C.
- the temperature reversible methyl cellulose having the molecular weight of 10 to 20 kDa can be obtained, for example, by a method comprising treating the cellulase to a molecular weight of 50 to 70 kDa methylcellulose and dialysis with a dialysis membrane.
- the drug that can be used in the temperature sensitive gel of the present invention may be any drug, but is preferably a hydrophilic drug, a protein drug or a nucleic acid based drug.
- the drug may be contained in an amount of 0.1% to 100% by weight relative to the total temperature sensitive gel.
- the present invention also provides a sustained release parenteral drug delivery composition comprising the thermosensitive gel and a hydrophilic drug.
- composition of the present invention is characterized by being administered parenterally, which means that the parenteral is intramuscular, intraperitoneal, abdominal, subcutaneous, vein or artery.
- composition for sustained release parenteral drug delivery of the present invention is typically formulated as an injection.
- the drug can be easily injected into the thermosensitive gel according to the present invention through a syringe, and the drug is gradually released after the injection into a hard gel state at the body temperature, thereby increasing the stability of the drug and administering a single-dose drug.
- the drug delivery efficiency to the target can be increased.
- parenteral drug delivery system is based on only low molecular weight natural polymer methylcellulose, there is no toxicity problem caused by the use of conventional salt salts, and thus, biocompatibility and biodegradability are excellent.
- the low molecular weight methyl cellulose of the present invention gels at the temperature of the body and not only slowly discharges the drug out of the body, but also the gel itself is gradually degraded in the body, which is changed into a low molecular material that is harmless to the body, and thus is discharged out of the body.
- There is no separate surgical removal procedure after the release of the drug and it is not necessary for frequent administration so that the drug is maintained in a single dose, so that the patient's convenience can be facilitated, and the formed gel is maintained for a long time so that the drug can be maintained for a desired period.
- It is very useful as a carrier of drugs because it is excellent in various effects such as being able to release.
- FIG. 1 is a schematic diagram of a low molecular weight methyl cellulose manufacturing process of the present invention.
- Figure 2 is a gel permeation chromatography (Gel Permeation Chromatography, GPC) results for the molecular weight of methylcellulose before cellulase enzyme treatment.
- Figure 3 is a gel permeation chromatography (Gel Permeation Chromatography, GPC) results for the molecular weight of methyl cellulose prepared after the cellulase enzyme treatment.
- Figure 4 is a low molecular methyl cellulose gel temperature measurement graph of the present invention.
- 5 is a viscosity graph of 20% hydrogel of the present invention with temperature.
- Figure 6 is a schematic diagram of the cytotoxicity test results and toxicity test results of the temperature-sensitive gel of the present invention.
- FIG. 7 is a graph showing the results of toxicity of ammonium sulfate (AS), sodium triphosphate (STPP) and sodium sulfate (SS) salt salts.
- AS ammonium sulfate
- STPP sodium triphosphate
- SS sodium sulfate
- FIG. 10 is a graph evaluating the effects of FGF21-containing hydrogel in type 2 diabetes animal model.
- Figure 11 is a photograph confirming the biodischarge capacity of the hydrogel of the present invention using a mouse.
- Solid is the dispersion of colloidal particles in a liquid
- the term “gel” has a pore of submicrometer dimensions and typically has an average length greater than 1 micrometer.
- an interconnected rigid network of polymer chains it refers to a semisolid phase that occurs spontaneously when the temperature of the polymer solution rises above the gelling temperature of the block copolymer.
- “Gelation temperature” means the temperature at which a biodegradable block copolymer undergoes reverse thermal gelation, below which the block copolymer is soluble in water and above this temperature the block copolymer undergoes a phase transition to increase viscosity or semisolid Form a gel.
- 'Gelling temperature' and 'inverse thermal gelling temperature' have the same meaning.
- Reverse (negative) thermal gelation is a phenomenon in which a block copolymer solution spontaneously increases in viscosity or converts into a semisolid gel when the solution temperature is increased above the copolymer gelling temperature. Gels include semisolid gel states and high viscosity states that exist above the gelling temperature. When cooled below the gelling temperature the gel is converted to a low viscosity solution. Cycling between solution and gel is repeated since the sol / gel transition is not related to changes in the chemical composition of the polymer system. All interactions that produce the gel are physical in nature and do not result in breakage or formation of covalent bonds.
- Biodegradable means that the block copolymer can be chemically degraded in the body to form non-toxic compounds. The rate of degradation is the same or different than the rate of drug release.
- biocompatible is meant a substance which interacts with the human body without undesirable subsequent effects.
- sustained release refers to the continuous release of a drug or therapeutic agent or any combination thereof over a period of time.
- Controlled release refers to the control of the rate and / or amount of drug or therapeutic agent delivered in accordance with the drug delivery formulation of the present invention. Controlled release can be continuous or discontinuous and / or linear or nonlinear. This may be achieved by the inclusion of one or more types of polymer compositions, drug loadings, excipients or degradation enhancers, or other modifiers, alone, in combination or in series to provide the desired effect.
- Drug means an organic or inorganic compound or substance that is bioactive and is used or modified for therapeutic purposes. Proteins, oligonucleotides, DNA and gene therapeutics are broadly included in the drug definition.
- Therapeutic agent refers to any compound or composition that, when administered to an organism (human or non-human animal), induces the desired pharmacological, immunogenic and / or physiological effects by local and / or systemic action.
- the term includes compounds or chemicals that are conventionally considered to be biopharmaceuticals that include drugs, vaccines, and molecules such as proteins, peptides, hormones, nucleic acids, gene constructs, and the like.
- Protein polypeptide
- oligopeptide and “protein” can be used equally when referring to peptides or protein drugs and are not limited to particular molecular weight, peptide sequence or length, bioactivity or therapeutic field.
- Therapeutic effect means any improvement in the disease of a subject, human or animal treated according to the method, and means a prophylactic or preventive effect, or a disease that can be detected by physical investigation, laboratory or mechanical methods And obtaining any alleviation in the severity of the signs and symptoms of the disease or illness.
- treatment means (i) an animal that is susceptible to disease, disease and / or disease but has not yet been diagnosed with disease or To prevent the occurrence of a disease, illness or illness in a human; (ii) inhibit a disease, disorder or condition, ie inhibit its progression; And / or (iii) alleviate a disease, disorder or condition, ie cause disease, disease and / or disease regression.
- the present inventors have found that sustained release of parenteral drugs is possible by enhancing biocompatibility and biodegradation by using a temperature sensitive gel based on small molecular weight methylcellulose, and completed the present invention.
- the present invention relates to a ubiquitous injection type temperature sensitive gel for drug delivery containing only low molecular weight natural polymer without salt salt.
- the present invention relates to a temperature-sensitive gel for parenteral drug delivery consisting of only temperature-reversible methyl cellulose having a molecular weight of 10 to 20 kDa.
- the temperature sensitive gel refers to a drug carrier including a polymer having a property of showing a phase change with a change in temperature.
- the natural polymer used in the drug delivery gel of the present invention has a block copolymer structure composed of a hydrophobic region having a high degree of substitution and a hydrophilic region having a low degree of substitution or no substitution in order to form a temperature-reversible physical gel in an aqueous solution. It is characterized by.
- the hydrophobic region locally stabilizes the water structure, and upon heating, the water structure is destroyed to enhance hydrophobic interactions, resulting in gelation.
- the natural polymer has a biodegradable property in vivo, in particular, in order to further increase such biodegradability, the present invention is characterized by using a small molecular weight natural polymer.
- the natural polymer used in the present invention is a temperature-reversible polysaccharide having a molecular weight of 10 to 20 kDa, preferably methyl cellulose.
- Methylcellulose is a hydrophobically modified nonionic cellulose derivative that forms a temperature reversible physical gel in aqueous solution.
- Methylcellulose is an inhomogeneous alternating block copolymer structure consisting of a highly substituted hydrophobic region and a less substituted or unsubstituted hydrophilic region (see Kundu, KK, Polymer. 42 (2001) 2015-2020). .
- the hydrophobic region causes the gelation phenomenon by destroying the water structure by heating to enhance hydrophobic interaction.
- Commercially available MC having a degree of substitution (DS) of 1.4 to 2.0 undergoes a sol-gel transition upon heating at a concentration of 1.0 to 2.5% of MC in water.
- methylcellulose MC
- MC methylcellulose
- additives such as polymers, non-electrolytes or salts. It was necessary to denature the gelation mechanism.
- the gelling temperature of methyl cellulose (MC) is 55 °C or more, in order to gel at a body temperature of about 37 °C or more, in order to lower the gelling temperature, conventionally increased the concentration of methyl cellulose (MC) or added with salts It was.
- concentration of methyl cellulose (MC) is increased, the viscosity of the solution is high, so handling is difficult.
- salt salts such as ammonium sulfate and sodium triphosphate, there is a problem of causing cytotoxicity when used in excess. It was.
- the inventors have found that through enzymatic treatment, the methylcellulose molecular weight is significantly reduced to 10-20 kDa, thereby lowering the gelling temperature to a body temperature in the range of 35-40 ° C.
- Low molecular weight methyl cellulose (MC) having a molecular weight of 10 to 20 kDa of the present invention can be obtained by reducing the molecular weight through, for example, an enzyme treatment such as cellulase. More specific process is shown in the schematic diagram in FIG.
- the methyl cellulose (MC) having a molecular weight of 10 to 20 kDa of the present invention may be referred to herein as "low molecular weight methyl cellulose".
- the low molecular weight methyl cellulose of the present invention also includes a methyl cellulose derivative that falls within the range of not losing the temperature sensitive properties.
- the temperature-sensitive gel of the present invention can be effectively used in sustained release drug carriers. In particular, it is more effective for hydrophilic drug delivery.
- a mixture of biodegradable low molecular weight methylcellulose and hydrophilic peptide / protein drugs and the like can be prepared as an aqueous copolymer solution below the methylcellulose gelling temperature to form a drug delivery liquid in which the drug is partially or completely dissolved.
- the low molecular weight methyl cellulose of the present invention can be gelled in the body without the addition of other salts, so it is very excellent in biocompatibility and biodegradability.
- Drug substances that may be included in the gel of the present invention include, for example, proteins, polypeptides, carbohydrates, inorganic substances, antibiotics, anti-neoplastics, local anesthetics, anti-angiogenic agents, vasoactive agents, anticoagulants, immunomodulators, cytotoxic agents , Antiviral agents, antibodies, neurotransmitters, psychoagonists, oligonucleotides, lipids, cells, tissues, tissues or cell aggregates, and combinations thereof.
- cancer chemotherapeutic agents such as cytokines, chemokines, lymphokines and indeed purified nucleic acids, and vaccines such as attenuated influenza viruses.
- purified nucleic acids that can be incorporated include genomic nucleic acid sequences, cDNA encoding proteins, expression vectors, antisense molecules and ribozymes that bind to complementary nucleic acid sequences to inhibit translation or transcription.
- drugs that can be used basically, in particular, hydrophilic drugs, protein drugs or nucleic acid-based drugs are more preferable among the drugs.
- thermosensitive gels of the present invention may also comprise one or more drugs or therapeutic agents for short-term therapeutic effects or treatments, wherein the drugs or therapeutic agents are prepared before, during or after dissolving the natural polymer in solution. It can be added to the polymer used to. Preferably, the drug or therapeutic agent is added prior to dissolution to promote more uniform dispersion or dissolution of the drug or therapeutic agent.
- a drug or therapeutic agent is included in the gel at about 0.1 to about 100 weight percent, preferably about 1 to about 50 weight percent, and more preferably about 10 to about 30 weight percent. However, the drug or therapeutic agent may be included in 0.01 to 95% by weight of the gel. The amount or concentration of drug or therapeutic agent contained in the gel will depend on the rate of absorption inactivation and release of the drug or therapeutic agent as well as the rate of delivery of the polymer in the gel.
- the temperature sensitive gel for drug delivery according to the present invention prepared by the above method, is liquid at room temperature. Immediately after injection into the subject, the gel becomes due to body temperature. Drugs or therapeutic agents contained within the temperature sensitive gel will diffuse into the extracellular matrix of the subject and will be released by controlled means to the target site.
- the present invention relates to a low molecular weight methyl cellulose and a method for producing a temperature sensitive gel using the same in another aspect.
- thermosensitive gels can be prepared using standard techniques known to those skilled in the art. Techniques, amounts, temperatures and times required to prepare the thermosensitive gel for drug delivery of Example 1 of the present invention will be known to those skilled in the art.
- the gel of the present invention may optionally further comprise a small amount of salt salts, preferably, it is preferable to prepare a hydrogel for drug delivery using only the low molecular weight methyl cellulose without salt salts.
- the sensitivity of the gel to various temperatures is measured using standard assays or techniques, such as viscometers, to measure viscosity and volume changes at various temperatures. Can be.
- the present invention includes a pharmaceutical composition for controlled drug release, comprising a plurality of drugs or therapeutic agents in a biodegradable and biocompatible gel.
- the present invention relates to a pharmaceutical composition for sustained release drug containing a thermosensitive gel containing a temperature-reversible methyl cellulose having a molecular weight of 10 to 20 kDa, and a drug of interest and its use.
- the temperature sensitive gels of the present invention can be formulated to be bioabsorbable, biodegradable, biocompatible.
- Bioabsorbable means that the polymer may disappear in the initial application in the body, without degradation or degradation of the dispersed polymer molecules.
- Biodegradability means that the polymer can be broken down or degraded in the body by hydrolysis or enzymatic degradation.
- Biocompatibility means that all of the ingredients are nontoxic in the body.
- Therapeutic drug delivery systems of the present invention provide for the delivery of a drug in the drug system by injection or other method suitable for a person or other mammal having a therapeutically effective disease state or condition (e.g., implantation, body cavity, or Incorporation, coating the tissue surface of the body or coating the surface of the implantable device), but in particular, the composition is preferably delivered parenterally.
- a therapeutically effective disease state or condition e.g., implantation, body cavity, or Incorporation, coating the tissue surface of the body or coating the surface of the implantable device
- the composition is preferably delivered parenterally.
- 'Parenteral' includes intramuscular, intraperitoneal, abdominal, subcutaneous, intravenous and intraarterial.
- compositions of the present invention may be representatively formulated in injection formulations.
- the gel In order to apply a temperature sensitive gel as an injection drug delivery system or a functional support for tissue regeneration, the gel should have low viscosity, fast gel formation, and low molecular weight to be easily discharged to the outside of the body. By using it, it is possible to maintain low viscosity and low molecular weight, which are one of the requirements of the biocompatibility and temperature sensitive gel.
- compositions of the invention may be injected or inserted into the body of a human or other mammal by any suitable method, preferably by injection through a hypodermic needle.
- the hydrogel is administered to a defined area or tissue to increase the local concentration of the drug to form a delayed release depot. In other applications, it may be applied topically to open surgery or trauma wounds, burns, or skin or other tissue surfaces.
- the present invention is characterized by a sustained release composition that allows the drug to be released slowly in the body when injected into a specific site in the body.
- thermosensitive gel of the present invention is suitable for use as a slow release of the drug and as a controlled release matrix.
- a biodegradable sustained release drug delivery system is provided.
- sustained release ie, prolonged release or controlled release
- a drug delivery system or composition introduced into the body space, that continuously releases one or more therapeutic streams over a predetermined time at a therapeutic level sufficient to achieve the desired therapeutic effect over a predetermined time.
- In one embodiment of the present invention has a drug release period of about 20 to 40 days it was confirmed that the drug release is possible.
- the hydrogel of the present invention is decomposed into a substance harmless to the human body after a certain period of time and is discharged to the outside through the kidneys, the specific composition of the present invention using a general syringe or catheter
- the drug When injected into the site, the drug is released slowly and the drug is maintained at a constant concentration for a long time in the circulating blood, so that the expression of the drug is excellent and there is no need for a separate surgical removal procedure for removing the drug carrier. .
- the drug or therapeutic agent may be released in a controlled manner to the target site of the subject.
- thermosensitive gel is used to provide site-specific release of a drug or therapeutic agent to a subject.
- the thermosensitive gel includes one or more drugs or therapeutic agents that can be administered to the subject, such that the drugs or therapeutic agents are released by diffusion from the gel and / or degradation of the gel.
- the dosage value of the composition will vary depending on the type and severity of the disease, disorder or condition being treated.
- the specific dosage regimen should be adjusted over time in accordance with the needs of the individual and the professional judgment of the person administering or directing the composition.
- In vivo administration can be based on in vitro release studies in cell culture or on in vivo animal models.
- the methods and compositions of the present invention provide for optimal delivery of the drug or therapeutic agent because it releases the drug or therapeutic agent in a controlled manner.
- the drug is delivered for the desired period of time. Slower and more constant rates of delivery may, in turn, result in a decrease in the frequency with which the drug or therapeutic agent should be administered to the animal.
- the rate of release of the drug or therapeutic agent depends on many factors, in particular on the rate of degradation of the biodegradable polymers that make up the gel. It also depends on the particle size of the drug or therapeutic agent. Thus, by adjusting the factors discussed above, decomposition, diffusion and controlled release can vary in a wide variety of ranges. For example, the release can be designed to occur over time, days, months.
- thermosensitive gel for parenteral drug delivery using the low molecular weight methyl cellulose of the present invention has high biocompatibility and biodegradability, is suitable for long-term sustained release formulations, and improves the stability and effectiveness of the drug. Very useful as a carrier.
- cellulase cellulase
- FIG. 1 A schematic diagram of the low molecular weight methyl cellulose manufacturing process of the present invention is shown in FIG. 1.
- the molecular weight of the methyl cellulose before cellulase treatment and the low molecular weight methyl cellulose of the present invention after the treatment were measured using gel permeation chromatography (GPC) and shown in FIGS. 2 and 3.
- the molecular weight of methyl cellulose before the enzyme treatment was about 64 kDa, but after the enzyme treatment, the molecular weight was reduced to almost 1/4 or less to 15 kDa.
- temperature sensitive hydrogels were prepared using only the low molecular weight methylcellulose obtained above and analyzed for their properties.
- the gel was prepared using methods known in the art. Briefly, the low molecular weight methyl cellulose prepared in Example 1 was mixed well with distilled water at 20% by weight to prepare a methyl cellulose gel, and then mixed well using a stirrer at low temperature (4 ° C.). At this time, since it does not melt at a high temperature due to the characteristics of the low molecular weight methyl cellulose, it was carried out at a low temperature of about 4 °C. As such, the mixture was mixed through a stirrer for about 1 hour and then stored at low temperature until use for later experiments.
- thermosensitive hydrogel could be prepared using only the low molecular weight methyl cellulose of the present invention without adding salt salts.
- the viscosity of the 20% hydrogel was measured in a rheometer and is shown in FIG. 5.
- 3T3-L1 cells were grown in a transwell plate, and then inserted into a gel to insert and observed.
- the cytotoxicity test schematic (top) and the results (bottom) are shown in FIG. 6.
- the low molecular weight methylcellulose hydrogel of the present invention was not toxic.
- ammonium sulfate (AS), sodium triphosphate (STPP), sodium sulfate (SS) in H9C2 cells Toxicity was analyzed. The results are shown in FIG.
- Ammonium sulfate (AS), sodium triphosphate (STPP), and sodium sulfate (Sodium sulfate, SS) salts were all toxic to cells at low concentrations.
- a protein (BSA, FGF21) and a peptide (Exenatide) were each encapsulated in the hydrogel prepared in Example 1, and a drug release test was conducted.
- Each drug was encapsulated in a hydrogel, placed in a microtube, and then solidified. Then, the phosphate buffer saline (PBS) was added to the gel, and the release was performed at 37 and 100 rpm.
- PBS phosphate buffer saline
- Streptozotocin (streptozotocin) was administered to mice to prepare a type 1 diabetic model, a formulation in which exenatide (exenatide) was encapsulated in a hydrogel and dissolved in phosphate buffered saline (Phosphate Buffer Saline (PBS)). Hydrogel was injected once and exenatide dissolved in PBS was administered daily for 5 days. After administration, changes in blood glucose were observed for a period of time. The result is shown in FIG.
- exenatide blood glucose is controlled to be injected every day because the half-life is very short in vivo, but when exenatide is infused and injected into the hydrogel of the present invention, the exenaide in the hydrogel for one week through one administration As the tide was released, it was confirmed that blood sugar was controlled.
- a high fat diet was continuously fed to mice to induce obesity, and then a blood sugar was measured to prepare a diabetes model.
- a fluorescent substance Cy5.5 was bonded to methyl cellulose, and then a gel was prepared by the method of Example 1. Thereafter, the gel was injected subcutaneously and observed for a certain period of time.
- the hydrogel of the present invention is slowly decomposed in the body and is converted into a low molecular substance that is harmless to the human body and is discharged out of the body. It can be seen that.
- the parenteral drug delivery system according to the present invention is based on only low molecular weight natural polymer methylcellulose, there is no toxicity problem caused by the use of conventional salt salts, and thus, biocompatibility and biodegradability are excellent.
- the low molecular weight methyl cellulose of the present invention gels at the temperature of the body and not only slowly discharges the drug out of the body, but also the gel itself is gradually degraded in the body, which is changed into a low molecular material that is harmless to the body, and thus is discharged out of the body.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (8)
- 염석염 없이 분자량 10 내지 20 kDa인 메틸셀룰로오스로 이루어진, 비경구 약물전달용 온도감응성 겔.
- 제1항에 있어서,상기 메틸셀룰로오스는 평균 분자량이 15 kDa인 것을 특징으로 하는 온도감응성 겔.
- 제1항에 있어서,상기 겔은 35 내지 40 ℃의 체내 온도 범위에서 형성되는 것을 특징으로 하는 온도감응성 겔.
- 제1항에 있어서,상기 약물이 친수성 약물, 단백질 약물 또는 핵산 기반 약물인 것을 특징으로 하는 비경구 약물전달용 온도감응성 겔.
- 제1항의 온도감응성 겔 및 친수성 약물, 단백질 약물 또는 핵산 기반 약물을 포함하는 서방형 비경구 약물 전달용 조성물.
- 제5항에 있어서,상기 비경구는 근육내, 복막내, 복부내, 피하, 정맥 또는 동맥인 것을 특징으로 하는 서방형 비경구 약물 전달용 조성물.
- 제5항에 있어서,상기 조성물은 주사제형으로 제제되는 것을 특징으로 하는 조성물.
- 분자량 50 내지 70 kDa 메틸셀룰로오스에 셀룰라아제를 처리하는 단계; 및 투석 멤브레인으로 투석하는 단계;를 포함하는 제1항의 분자량 10 내지 20 kDa인 메틸셀룰로오스 제조방법.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/890,330 US9700630B2 (en) | 2013-05-10 | 2014-05-09 | Low molecular weight methyl cellulose-based parenteral drug delivery system |
CN201480026587.1A CN105188668B (zh) | 2013-05-10 | 2014-05-09 | 基于低分子量甲基纤维素的肠胃外药物递送系统 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2013-0053165 | 2013-05-10 | ||
KR20130053165A KR20140133724A (ko) | 2013-05-10 | 2013-05-10 | 저분자 메틸셀룰로오스 기반의 비경구 약물 전달 시스템 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014182101A1 true WO2014182101A1 (ko) | 2014-11-13 |
Family
ID=51867500
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2014/004120 WO2014182101A1 (ko) | 2013-05-10 | 2014-05-09 | 저분자 메틸셀룰로오스 기반의 비경구 약물 전달 시스템 |
Country Status (4)
Country | Link |
---|---|
US (1) | US9700630B2 (ko) |
KR (1) | KR20140133724A (ko) |
CN (1) | CN105188668B (ko) |
WO (1) | WO2014182101A1 (ko) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108014342A (zh) * | 2016-11-04 | 2018-05-11 | 广州共禾医药科技有限公司 | 一种纤维素醚缓控释制剂质量分析供试品溶液的制备方法 |
US10357456B2 (en) * | 2016-03-24 | 2019-07-23 | Industry-University Cooperation Foundation Hanyang University | Parenteral bioactive substance delivery composition based on low molecular weight methyl cellulose |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102037405B1 (ko) * | 2016-03-24 | 2019-11-27 | 한양대학교 산학협력단 | 저분자 메틸셀룰로오스 기반의 비경구 생리활성물질 전달용 조성물 |
US20220031623A1 (en) | 2018-12-18 | 2022-02-03 | DDP Specialty Electronic Materials US, Inc. | A sustained release composition comprising a methylcellulose |
CN114304384A (zh) * | 2021-12-02 | 2022-04-12 | 石玲青 | 一种动物咬胶食品及其制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100813224B1 (ko) * | 2007-08-24 | 2008-03-13 | 한양대학교 산학협력단 | 단백질 약물전달용 온도 가역성 코아세르베이트 조합 겔 |
KR20100097075A (ko) * | 2009-02-25 | 2010-09-02 | 한양대학교 산학협력단 | 소수성 및 친수성 약물 전달용 유비쿼터스 주입형 온도감응성 겔 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3856941A (en) * | 1972-05-23 | 1974-12-24 | Sobel J | Astringent gel, its preparation and use |
-
2013
- 2013-05-10 KR KR20130053165A patent/KR20140133724A/ko active Application Filing
-
2014
- 2014-05-09 US US14/890,330 patent/US9700630B2/en active Active
- 2014-05-09 WO PCT/KR2014/004120 patent/WO2014182101A1/ko active Application Filing
- 2014-05-09 CN CN201480026587.1A patent/CN105188668B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100813224B1 (ko) * | 2007-08-24 | 2008-03-13 | 한양대학교 산학협력단 | 단백질 약물전달용 온도 가역성 코아세르베이트 조합 겔 |
KR20100097075A (ko) * | 2009-02-25 | 2010-09-02 | 한양대학교 산학협력단 | 소수성 및 친수성 약물 전달용 유비쿼터스 주입형 온도감응성 겔 |
Non-Patent Citations (3)
Title |
---|
BHOWMIK, M. ET AL.: "Effect of salts on gelation and drug release profiles of methylcellulose-based ophthalmic thermo-reversible in situ gels", PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY, vol. 16, no. 4, 2011, pages 385 - 391 * |
ITOH, K. ET AL.: "Effect of D-sorbitol on the thermal gelation of methylcellulose formulations for drug delivery", CHEMICAL AND PHARMACEUTICAL BULLETIN, vol. 58, no. 2, 2010, pages 247 - 249 * |
KUMAR, S. ET AL.: "In situ-forming gels for ophthalmic drug delivery", JOURNAL OF OCULAR PHARMACOLOGY, vol. 10, no. 1, 1994, pages 47 - 56, XP001011244 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10357456B2 (en) * | 2016-03-24 | 2019-07-23 | Industry-University Cooperation Foundation Hanyang University | Parenteral bioactive substance delivery composition based on low molecular weight methyl cellulose |
CN108014342A (zh) * | 2016-11-04 | 2018-05-11 | 广州共禾医药科技有限公司 | 一种纤维素醚缓控释制剂质量分析供试品溶液的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
US20160106848A1 (en) | 2016-04-21 |
KR20140133724A (ko) | 2014-11-20 |
CN105188668A (zh) | 2015-12-23 |
CN105188668B (zh) | 2019-06-28 |
US9700630B2 (en) | 2017-07-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2014182101A1 (ko) | 저분자 메틸셀룰로오스 기반의 비경구 약물 전달 시스템 | |
DK174804B1 (da) | Fremgangsmåde til fremstilling af selvdispergerbare blokcopolymerer, copolymerlægemiddelpulver, fremgangsmåde til fremstilling heraf samt fremgangsmåder til fremstilling af frosne, stabile, vandige dispersioner af copolymer og lægemiddel | |
US20100226985A1 (en) | Viscoelastic aqueous gels comprising microspheres | |
CA2419067C (en) | Injectable composition comprising benzimidazole compound and strong alkali | |
AU2015206597B2 (en) | Thermosensitive hydrogel collagenase formulations | |
US20090202642A1 (en) | Drug Delivery System Comprising Microparticles and Gelation System | |
BRPI0606514A2 (pt) | composiÇço farmacÊutica para liberaÇço controlada, kit farmacÊutico, mÉtodo para a preparaÇço da composiÇço, e, uso da composiÇço | |
JP2007537249A (ja) | 荷電ポリマーを含むゲル組成物 | |
US9393309B2 (en) | Self-gelatinizable nucleic acid | |
Raj et al. | Oral insulin–a perspective | |
KR102192908B1 (ko) | 온도감응형 하이드로겔을 이용한 서방성 약물전달체 제조방법 | |
Lu et al. | Experimental research A novel ropivacaine-loaded in situ forming implant prolongs the effect of local analgesia in rats | |
KR101898816B1 (ko) | 저분자 메틸셀룰로오스 기반의 비경구 약물 전달 시스템 | |
CN103877584A (zh) | 一种羧甲基壳聚糖聚乳酸化学水凝胶药物载体的制备方法 | |
JPH04507412A (ja) | 薬学上の化合物 | |
Yadav et al. | Modulation of physicochemical properties of polymers for effective insulin delivery systems | |
KR20210121576A (ko) | 고분자 마이크로 입자, 고분자 마이크로 입자의 제조방법, 이를 포함하는 의료용 조성물, 미용 조성물, 의료 용품 및 미용 용품 | |
Torabi et al. | An innovative approach to fabricate a thermosensitive melatonin‐loaded conductive pluronic/chitosan hydrogel for myocardial tissue engineering | |
EP4008353A1 (en) | Pharmaceutical composition for otic administration | |
Lim et al. | Biodegradable Thermogelling Polymers for Drug Delivery | |
KR102101144B1 (ko) | 마이크로니들에 포함된 약물의 약물동태학적 성능을 개선하는 조성물 | |
CN112336682B (zh) | 具有缓控释药物作用的可注射复合载体与组合物及制备方法 | |
WO2024117274A1 (ko) | 유전자 전달 복합체 | |
Vikas et al. | Alginate-Based Hydrogels as Drug Carriers | |
Takata | Studies on clarification of gelation mechanism of temperature-responsive biodegradable smart biomaterials and their utility as drug releasing devices |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201480026587.1 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14795296 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14890330 Country of ref document: US |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205 DATED 22-02-2016) |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 14795296 Country of ref document: EP Kind code of ref document: A1 |